Manufacture and Marketing of so called orphan drugs

There are many diseases and conditions, such as Tourett Syndrome, Myoclonus, Muscular Dystrophy, and Huntington's disease, that affect such a small number of people within the US borders that the diseases and conditions is classified as "rare". Since there is such a small market (people), that are effected by any one rare disease or condition, a drug company which develops an orphan drug may reasonably expect the drug to generate relatively small sales/profits, in …

…constitute a 50% federal tax credit for clinical research cost, exemption from FDA registration fees, exclusive market for seven years, protocol assistance and congressional grants of over 40 million. As you review these "numbers" it become very clear that obviously businesses have to be mandated to do the right thing. Refernce: Williams, Stephen. J. / Torrens, Paul R. (2000). " Health Services", Albany, New York, N.Y. O.C.Ferrell, John Fraedrich, LindaFerrell, (2005), "Business Ethics" (6th ed) New York, NY